Stockreport

Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities

Neoleukin Therapeutics, Inc.  (NLTX) 
PDF SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational m [Read more]